ÀÌ°æ¹Î

ÀÌ°æ¹Î

ÀÌ°æ¹Î ±³¼öÀÇ Áø·á½Ã°£Ç¥ Áø·á¿¹¾à

Áø·á°ú/¼¾ÅÍ ¿ù È­ ¼ö ¸ñ ±Ý Åä Àü¹®Áø·á°ú¸ñ
Á¾¾ç³»°ú
¿ÀÈÄ
-
¿ÀÀü
-
¿ÀÀü
- ºñ´¢±â¾Ï, ºÎÀξÏ, ³úÁ¾¾ç, Àü¸³¼±¾Ï, ¿ø¹ßºÒ¸í¾Ï (¾Ïº´¿ø 3F Áø·á)
¾Ïº´¿ø(3F)
¿ÀÈÄ
-
¿ÀÀü
-
¿ÀÀü
- ºñ´¢±â¾Ï, ºÎÀξÏ, ³úÁ¾¾ç, Àü¸³¼±¾Ï, ¿ø¹ßºÒ¸í¾Ï

ÀÌ°æ¹Î ±³¼öÀÇ »ó¼¼Á¤º¸

ÇзÂ

more
  • 2007 .03  ~  2013 .02  :  °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇлç
  • 2016 .03  ~  2018 .02  :  ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇм®»ç

°æ·Â

more
  • 2018 .03  ~  2019 .08  :  ¼­¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú ÀÓ»ó°­»ç
  • 2019 .09  ~  2020 .02  :  °í´ë±¸·Îº´¿ø Ç÷¾×Á¾¾ç³»°ú ÀÓ»ó°­»ç
  • 2020 .03  ~   :  °í´ë±¸·Îº´¿ø Ç÷¾×Á¾¾ç³»°ú ÀÓ»óÁ¶±³¼ö´ë¿ì

¼ö»ó³»¿ª

more
  • 2019 .05  :  Çѱ¹¾ÏÇмúÀç´Ü Çмú»ó

ÇÐȸȰµ¿

more
  •  ~   :  ´ëÇѳ»°úÇÐȸ Á¤È¸¿ø
  •  ~   :  ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¤È¸¿ø
  •  ~   :  ´ëÇѾÏÇÐȸ Á¤È¸¿ø
  •  ~   :  À¯·´Á¾¾ç³»°úÇÐȸ Á¤È¸¿ø

³í¹®

more
  • [SCI] (The clinical outcomes of rituximab biosimilar CT-P10 (Truxima((R))) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.)
  • [SCI] (The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions)
  • [SCI] (Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.)
  • [SCI] (Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.)
  • [SCI] (Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis)
  • [SCI] (Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.)

ÃÖÁ¾¼öÁ¤ÀÏ : 2023.05.09